Revolutionizing Obesity Treatment | Metsera
Discover scalable, innovative therapies for obesity. Our next-gen NuSH treatments offer effective, convenient solutions to empower lasting weight loss. Learn more today!
Metsera GLP-1 data slice reveals 7.5% weight loss at 36 days
Sep 24, 2024 · For patients receiving Metsera’s investigational injection at the 1.2-mg dose, weight loss continued after 36 days, with an 8.1% cumulative weight loss at Day 57, or four …
Metsera Touts ‘Powerful’ Weight Loss Results—Again
Jan 7, 2025 · Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just over 11% average body weight reduction at 12 …
Metsera links GLP-1 drug to 11% weight loss after 12 weeks
Jan 7, 2025 · Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some of its $215 million war chest to assess monthly …
Metsera follows up phase 1 weight loss data with $215M series B
Nov 13, 2024 · The biotech said it would use the cash to “further accelerate” a portfolio led by its GLP-1 receptor agonist MET-097, which was linked to a 7.5% reduction in body weight over …
New Weight Loss Biotech Metsera Stuns with 7.5% Weight Loss …
Sep 24, 2024 · Five months after launching, Metsera is making waves with Phase I results for a long-acting GLP-1 injectable showing a 7.5% reduction in body weight at day 36. The biotech …
Metsera links long-acting GLP-1 shot to 7.5% weight loss at 36 …
Jan 2, 2025 · For patients receiving Metsera’s investigational injection at the 1.2-mg dose, weight loss continued after 36 days, with an 8.1% cumulative weight loss at Day 57, or four weeks …
Metsera Announces Positive Topline Phase 2a Clinical Data for its …
Jan 7, 2025 · Positive 12-week results from a Phase 2a trial demonstrated substantial placebo-adjusted weight loss of up to 11.3% in the 1.2mg cohort at day 85 and was generally well …
Metsera’s Long-Acting GLP-1 Drug Shows Promising 7.5% Weight Loss …
Sep 24, 2024 · Metsera's Phase 1 trial of MET-097, a long-acting GLP-1 receptor agonist, demonstrated a 7.5% reduction in body weight from baseline at day 36. The drug's 380-hour …
Metsera’s touts ‘powerful’ weight loss results — again
Jan 7, 2025 · Months after posting weight loss of 7.5 percent at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just over 11 percent average body weight …